Please assess the completion status of the following clinical trial:

Trial Title: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate with radiographic evidence of metastatic disease.~* Willingness to undergo a baseline tumor biopsy.~* Castrate levels of testosterone (testosterone \< 50 ng/dL) on androgen deprivation therapy (ADT) with evidence of progression on ADT. GnRH therapy will be continued for those on it at baseline~* Patient must have suspected tumor in an area that is safe to biopsy.~* Other prior hormonal interventions or experimental approaches are allowed. These therapies must have been discontinued for a minimum of 28 days with cancer progression.~* Prior or concurrent use of bisphosphonates is allowed.~* One prior non-taxane chemotherapy allowed~* ≥ 3 weeks since major surgery; ≥ 4 weeks since radiotherapy; ≥ 8 weeks since prior strontium-89 or samarium 153~* Performance Status: ECOG 0 or 1~* ANC \> 1,500/_l; platelets \> 100,000/_l; total Bilirubin \< upper limit of normal; AST and ALT \< 3 x upper limits of normal; creatinine \< 1.5 x upper limits of normal; total fasting cholesterol \< 350 mg/dl; total triglycerides \< 300 mg/dl~Exclusion Criteria:~* Ongoing oral steroid use. Patients with a history of oral steroid use are eligible as long as the steroids have been discontinued prior to study entry. Ongoing topical and/or inhaled steroid use is allowed.~* Prior taxane chemotherapy~* Prior mTOR inhibitors (RAD001, rapamycin, CCI-779)~* Currently active second malignancy other than non-melanoma skin cancer.~* Ongoing peripheral neuropathy of Grade 2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 Followed by RAD001 + Docetaxel (Type: EXPERIMENTAL): RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).